The risk factors of secondary infection in breast cancer or lung cancer patients with chemotherapy-induced degree Ⅳ neutropenia: a case-control study_Chinese Journal of Evidence-Based Medicine

Authors：

FAN Di ¹ , YOU Haisheng ¹ , LI Hong ¹ , HE Yinli ¹ , TANG Lina ¹ , ZHANG Wei ¹ ,  LV Jun ²

1. Department of Pharmacy, the First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, 710061, P.R.China;
2. Clinical Research Centre, the First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, 710061, P.R.China;

Corresponding?author：

LV Jun, Email: lujun2006@xjtu.edu.cn

Keywords：

Breast cancer; Lung cancer; Neutropenia; Infection; Case-control study

DOI：

10.7507/1672-2531.201706037

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objectives To analyze the risk factors of secondary infections in breast cancer or lung cancer patients with chemotherapy-induced degree Ⅳ neutropenia, so as to provide reference for clinical treatment. Methods The case-control study design was used. Thirty-seven in-patients of breast cancer or lung cancer with secondary infections and 87 in-patients without secondary infection in the First Affiliated Hospital of Xi’an Jiaotong University from January to December 2014 were enrolled as study population. We collected the retrospective information and analyzed the risk factors of secondary infection with chemotherapy-induced degree Ⅳ neutropenia using factors under univariate analysis and logistic regression analysis. Results Single factor analysis showed that the patients whose MASCC<21 the had higher infection risks (P<0.05). For breast cancer patients with degree Ⅳ neutropenia, secondary infection risk of first two chemotherapy cycles was 2.87 times of subsequent cycles of chemotherapy. For lung cancer patients with degree Ⅳ neutropenia, invasive procedures and preventive use of antibiotics increased risk of infection (P<0.05). Logistic regression analysis showed MASCC score and chemotherapy cycles were significantly associated with secondary infection in breast cancer degree Ⅳ neutropenia patients (P<0.05). Invasive procedures were significantly correlated to secondary infection of patients with lung cancer degree Ⅳ neutropenia (P<0.05). Conclusions MASCC score and chemotherapy cycles are the risk factors of infection in breast cancer patients with degree Ⅳ neutropenia, and invasive procedures are the independent risk factors of infection in lung cancer patients with degree Ⅳ neutropenia.

Citation： FAN Di, YOU Haisheng, LI Hong, HE Yinli, TANG Lina, ZHANG Wei, LV Jun. The risk factors of secondary infection in breast cancer or lung cancer patients with chemotherapy-induced degree Ⅳ neutropenia: a case-control study. Chinese Journal of Evidence-Based Medicine, 2018, 18(4): 306-310. doi: 10.7507/1672-2531.201706037 Copy

1.	李亞麗, 肖佳靈, 楊克虎, 等. 卡培他濱聯合多西紫杉醇治療轉移性乳腺癌的系統評價. 中國循證醫學雜志, 2009, 9(8): 893-898.
2.	米登海, 李征, 田金徽, 等. 熱放化三聯療法治療非小細胞肺癌的 Meta 分析. 中國循證醫學雜志, 2011, 11(11): 1262-1267.
3.	王大志, 莊安士, 張書瑜. 抗腫瘤藥與呼吸系統惡性腫瘤化療患者骨髓抑制發生風險的 Logistic 回歸分析. 藥物流行病學雜志, 2012, 21(8): 365-367.
4.	李莉, 張萍, 康煥珍, 等. 腫瘤化療骨髓抑制期醫院感染的危險因素分析. 中華醫院感染學雜志, 2013, 23(18): 4394-4398.
5.	常瑞, 張慧敏. 腫瘤患者化療期間Ⅳ度骨髓抑制致院內感染的護理. 中國臨床護理, 2015, 7(4): 333-334.
6.	ESMO. ESMO recommendations for the application of hematopoietic growth factors (rGFs). Ann Oncol, 2001, 12(9): 1219-1220.
7.	胡薩薩, 尤海生. 化療致肺癌患者粒細胞減少危險因素的回顧性分析. 藥物流行病學, 2015, 24(6): 356-357.
8.	程伏林, 胡名柏, 袁宏銀. 化療所致粒細胞缺乏癥患者醫院感染危險因素的多因素 Cox 模型分析. 中華醫院感染學雜志, 2002, 12(5): 327-328.
9.	中國醫學會血液學分會. 中國粒細胞缺乏伴發熱患者抗菌藥物臨床應用指南. 中國血液學雜志, 2016, 37(5): 353-358.
10.	阮燕萍. 化療致粒細胞缺乏癥者發熱及感染的病例對照研究. 杭州: 浙江大學, 2007: 11, 18-19.
11.	Combariza JF, Lombana M, Pino LE, et al. C-reactive protein and the MASCC risk index identify high-risk patients with febrile neutropenia and hematologic neoplasms. Support Care Cancer, 2015, 23(4): 1009-1013.
12.	Klastersky J, Paesmans M. The Multinational Association for Supportive Care in Cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients. Surport Care Cancer, 2013, 21(5): 1487-1495.
13.	余樹娥, 汪蓓, 徐建華. rhG-GSF 對腫瘤患者化療后白細胞減少及粒細胞缺乏的療效. 湖南醫學, 2002, 19(2): 100-101.
14.	王軍, 劉勇. MASCC 危險指數評分和降鈣素原應用于血液病化療后粒細胞缺乏伴發熱的價值. 實用醫學雜志, 2015, 31(8): 1277-1279.
15.	阮艷萍, 張文英. 化療致粒細胞缺乏癥患者發熱與感染的關系. 癌癥, 2008, 27(8): 879-881.
16.	李偉偉, 崔艷慧, 蔡衛梅. 肺癌患者化療期間發生感染的相關危險因素分析. 中國醫院感染學雜志, 2013, 23(6): 1277-1278.
17.	張強. 細胞集落刺激因子和抗菌藥物預防化療所致粒細胞缺乏癥患者院內感染的療效觀察. 中國實驗和臨床感染病雜志, 2013, 7(4): 108-109.
18.	程伏林, 胡名柏, 林從堯, 等. 化療致粒細胞缺乏癥患者的院內感染. 實用癌癥雜志, 2001, 16(6): 613.

1. 李亞麗, 肖佳靈, 楊克虎, 等. 卡培他濱聯合多西紫杉醇治療轉移性乳腺癌的系統評價. 中國循證醫學雜志, 2009, 9(8): 893-898.
2. 米登海, 李征, 田金徽, 等. 熱放化三聯療法治療非小細胞肺癌的 Meta 分析. 中國循證醫學雜志, 2011, 11(11): 1262-1267.
3. 王大志, 莊安士, 張書瑜. 抗腫瘤藥與呼吸系統惡性腫瘤化療患者骨髓抑制發生風險的 Logistic 回歸分析. 藥物流行病學雜志, 2012, 21(8): 365-367.
4. 李莉, 張萍, 康煥珍, 等. 腫瘤化療骨髓抑制期醫院感染的危險因素分析. 中華醫院感染學雜志, 2013, 23(18): 4394-4398.
5. 常瑞, 張慧敏. 腫瘤患者化療期間Ⅳ度骨髓抑制致院內感染的護理. 中國臨床護理, 2015, 7(4): 333-334.
6. ESMO. ESMO recommendations for the application of hematopoietic growth factors (rGFs). Ann Oncol, 2001, 12(9): 1219-1220.
7. 胡薩薩, 尤海生. 化療致肺癌患者粒細胞減少危險因素的回顧性分析. 藥物流行病學, 2015, 24(6): 356-357.
8. 程伏林, 胡名柏, 袁宏銀. 化療所致粒細胞缺乏癥患者醫院感染危險因素的多因素 Cox 模型分析. 中華醫院感染學雜志, 2002, 12(5): 327-328.
9. 中國醫學會血液學分會. 中國粒細胞缺乏伴發熱患者抗菌藥物臨床應用指南. 中國血液學雜志, 2016, 37(5): 353-358.
10. 阮燕萍. 化療致粒細胞缺乏癥者發熱及感染的病例對照研究. 杭州: 浙江大學, 2007: 11, 18-19.
11. Combariza JF, Lombana M, Pino LE, et al. C-reactive protein and the MASCC risk index identify high-risk patients with febrile neutropenia and hematologic neoplasms. Support Care Cancer, 2015, 23(4): 1009-1013.
12. Klastersky J, Paesmans M. The Multinational Association for Supportive Care in Cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients. Surport Care Cancer, 2013, 21(5): 1487-1495.
13. 余樹娥, 汪蓓, 徐建華. rhG-GSF 對腫瘤患者化療后白細胞減少及粒細胞缺乏的療效. 湖南醫學, 2002, 19(2): 100-101.
14. 王軍, 劉勇. MASCC 危險指數評分和降鈣素原應用于血液病化療后粒細胞缺乏伴發熱的價值. 實用醫學雜志, 2015, 31(8): 1277-1279.
15. 阮艷萍, 張文英. 化療致粒細胞缺乏癥患者發熱與感染的關系. 癌癥, 2008, 27(8): 879-881.
16. 李偉偉, 崔艷慧, 蔡衛梅. 肺癌患者化療期間發生感染的相關危險因素分析. 中國醫院感染學雜志, 2013, 23(6): 1277-1278.
17. 張強. 細胞集落刺激因子和抗菌藥物預防化療所致粒細胞缺乏癥患者院內感染的療效觀察. 中國實驗和臨床感染病雜志, 2013, 7(4): 108-109.
18. 程伏林, 胡名柏, 林從堯, 等. 化療致粒細胞缺乏癥患者的院內感染. 實用癌癥雜志, 2001, 16(6): 613.

Chinese Journal of Evidence-Based Medicine

The risk factors of secondary infection in breast cancer or lung cancer patients with chemotherapy-induced degree Ⅳ neutropenia: a case-control study

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content